Synairgen (SYNG)

London
24.50
-1.50(-5.77%)
  • Volume:
    778,528
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    24.32 - 25.22

SYNG Overview

Prev. Close
26
Day's Range
24.32-25.22
Revenue
-
Open
25.12
52 wk Range
10-223.8
EPS
-0.24
Volume
778,528
Market Cap
49.34M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
918,819
P/E Ratio
-
Beta
-7.41
1-Year Change
-82.28%
Shares Outstanding
201,374,975
Next Earnings Date
27 Sept 2022
What is your sentiment on Synairgen?
or
Market is currently closed. Voting is open during market hours.

Synairgen News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Synairgen Analysis

Synairgen Company Profile

Synairgen Company Profile

Employees
24

Synairgen plc is a drug discovery and development company. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The Company is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The Company is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The Company offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • https://www.marketwatch.com/story/synairgen-shares-rise-on-positive-analysis-of-phase-3-covid-19-treatment-trial-271652687610
    0
    • https://www.synairgen.com/media/synairgen-presents-at-ats-2022
      0
      • Presenting to the ATS today, also rumours for a takeover…
        0
        • Though brief, interesting read and move in the right direction: https://www.synairgen.com/media/presentation-at-eccmid
          0
          • New promosing drug on the market in the name of VERU. Short Synairgen under 10
            1
            • Polygon position, Polygon Global Partners LLP 50,927,428 Ordinary shares (25.3%). Major shareholder, in at different levels, will they sell out, NOPE
              0
              • Why shouldnt there be a recovery? Polygon still have a major position and speaks volumes, IMO. On unpteen occasions i have said the company are not just covid related researches but also many lung related conditions are u der the microscope. Defo HOLD
                0
                • recovery?
                  0
                  • Indeed, oops
                    0
                    • oops
                      0